Table 3.

CBR in BCL2-high, BCL2-low, PIK3CA-wild-type, and PIK3CA-mutant subgroups.

	BCL2-high		BCL2-low		PIK3CA-wild-type		PIK3CA-mutant
	Venetoclax plus fulvestrant	Fulvestrant	Venetoclax plus fulvestrant	Fulvestrant	Venetoclax plus fulvestrant	Fulvestrant	Venetoclax plus fulvestrant	Fulvestrant
	n = 33	n = 33	n = 18	n = 18	n = 29	n = 31	n = 19	n = 14
CBR, n (%)	6 (18.2)	6 (18.2)	0	1 (5.6)	6 (20.7)	3 (9.7)	0	2 (14.3)
Risk difference (%)	0		–5.56		11.01		–14.29
95% CI	–21.64 to 21.64		–21.69 to 10.58		–10.37 to 32.40		–38.82 to 10.25

Note: ITT population with baseline measurable disease.

Abbreviations: BCL2, B-cell lymphoma 2; CBR, clinical benefit rate; CI, confidence interval; ITT, intention-to-treat.